Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec;46(1):2338566.
doi: 10.1080/0886022X.2024.2338566. Epub 2024 Apr 24.

Shenkang injection for the treatment of acute kidney injury: a systematic review and meta-analysis

Shengchun Liao  1 , Yurou Chen  1 , Shuting Wang  1 , Chen Wang  1 , Chaoyang Ye  2
Affiliations
Meta-Analysis

Shenkang injection for the treatment of acute kidney injury: a systematic review and meta-analysis

Shengchun Liao et al. Ren Fail. 2024 Dec.

Abstract

Objective: Shenkang injection (SKI) has been widely used in China for many years for the treatment of kidney disease. The objective of this systematic review was to assess the efficacy of Shenkang injection for the treatment of acute kidney injury (AKI).

Methods: A search was conducted across seven databases, encompassing data from the inception of each database through October 8th, 2023. Randomized controlled trials comparing SKI-treated AKI patients with control subjects were extracted. The main outcome measure was serum creatinine (SCr) levels. Secondary outcomes included blood urea nitrogen (BUN), serum cystatin C (CysC), 24-h urine protein (24 h-Upro) levels, APACHE II score and adverse reactions.

Results: This meta-analysis included eleven studies, and the analysis indicated that, compared with the control group, SKI significantly decreased SCr [WMD = -23.31, 95% CI (-28.06, -18.57); p < 0.001]; BUN [WMD = -2.07, 95% CI (-2.56, -1.57); p < 0.001]; CysC [WMD = -0.55, 95% CI (-0.78, -0.32), p < 0.001]; 24-h urine protein [WMD = -0.43, 95% CI (-0.53, -0.34), p < 0.001]; and the APACHE II score [WMD = -3.07, 95% CI (-3.67, -2.48), p < 0.001]. There was no difference in adverse reactions between the SKI group and the control group [RR = 1.32, 95% CI (0.66, 2.63), p = 0.431].

Conclusion: The use of SKI in AKI patients may reduce SCr, BUN, CysC, 24-h Upro levels, and APACHE II scores in AKI patients. The incidence of adverse reactions did not differ from that in the control group. Additional rigorous clinical trials will be necessary in the future to thoroughly evaluate and establish the effectiveness of SKI in the treatment of AKI.

Keywords: Acute kidney injury; Shenkang injection; meta-analysis; systematic review; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Risk bias of graph.
Figure 2.
Figure 2.
Risk bias of summary.
Figure 3.
Figure 3.
PRISMA flow diagram. SCr
Figure 4.
Figure 4.
Forrest plot of SCr.
Figure 5.
Figure 5.
Funnel plot of SCr. Subgroup of Scr
Figure 6.
Figure 6.
Subgroup by age of SCr.
Figure 7.
Figure 7.
Subgroup by treatment of SCr.
Figure 8.
Figure 8.
Subgroup by hemodialysis of SCr.
Figure 9.
Figure 9.
Subgroup by immunosuppressant of SCr. BUN
Figure 10.
Figure 10.
Forrest plot of BUN.
Figure 11.
Figure 11.
Funnel plot of BUN. CysC
Figure 12.
Figure 12.
Forrest plot of CysC.
Figure 13.
Figure 13.
Funnel plot of CysC. 24h-Upro
Figure 14.
Figure 14.
Forrest plot of 24-hour urine protein.
Figure 15.
Figure 15.
Funnel plot of 24-hour urine protein. APACHE II SCORE
Figure 16.
Figure 16.
Forrest plot of APACHE II SCORE.
Figure 17.
Figure 17.
Funnel plot of APACHE II SCORE. Adverse Reactions
Figure 18.
Figure 18.
Forrest plot of adverse reactions.
Figure 19.
Figure 19.
Funnel plot of adverse reactions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sato Y, Yanagita M.. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol. 2018;315(6):1–16. doi: 10.1152/ajprenal.00195.2018. Epub 2018 Aug 29. - DOI - PubMed
    1. Moore PK, Hsu RK, Liu KD.. Management of acute kidney injury: core curriculum 2018. Am J Kidney Dis. 2018;72(1):136–148. doi: 10.1053/j.ajkd.2017.11.021. - DOI - PubMed
    1. Matuszkiewicz-Rowińska J, Małyszko J.. Acute kidney injury, its definition, and treatment in adults: guidelines and reality. Pol Arch Intern Med. 2020;130(12):1074–1080. doi: 10.20452/pamw.15373. - DOI - PubMed
    1. Kidney Disease: improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group . Kdigo clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138. doi: 10.1038/kisup.2012.1. - DOI
    1. Chawla LS, Bellomo R, Bihorac A, Acute Disease Quality Initiative Workgroup 16 ., et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257. doi: 10.1038/nrneph.2017.2. - DOI - PubMed